AGP Wire

AGP

The Business Research Company says the global market for Elitek, sold as Fasturtec outside the U.S., is set for notable growth through 2035 as leukemia cases rise, healthcare spending increases and oncology support care expands.

AGP

GenBio will participate in BIO-Europe 2026 in Cologne, Germany, as it looks to expand international business development and pursue scientific collaborations, licensing deals and strategic transactions.

AGP

Automotive Cloud’s 2026 dashboard tracks vehicle sales across 58 countries and shows how uneven the EV transition remains across major markets.

AGP

Practical DevSecOps is promoting its Certified Security Champion program as companies race toward the EU Cyber Resilience Act’s final compliance deadline in December 2027. The move comes as the law already requires 24-hour vulnerability reporting…

AGP

The EU co-funded SNACK SMART campaign was presented in Madrid on Oct. 6, 2026, bringing together fruit trade, media and agri-food professionals to promote fresh fruit in everyday diets.

AGP

The AI-driven gamified language therapy market is projected to grow from $2.27 billion in 2026 to $5.09 billion by 2030, according to The Business Research Company.

AGP

FusionAuth says European demand for data sovereignty and tenant isolation is driving rapid growth, prompting the identity platform to set up its first dedicated sales team in the UK. The company also reported 48% year-over-year growth in…

AGP

Konecta was recognized by Everest Group as a Major Contender in its Digital Workplace Services PEAK Matrix assessment for Europe, marking the company’s first inclusion in the ranking.

AGP

Global demand for Ebola preparedness is pushing the Ervebo vaccine market toward faster growth through 2035, according to The Business Research Company.

AGP

The Business Research Company says the global Esperoct market is set to expand through 2035, driven by rising hemophilia A diagnoses, broader use of extended half-life therapies and more homecare treatment.

AGP

The Business Research Company says the AI-powered rare disease diagnosis market is set to surge from $2.56 billion in 2026 to $7.08 billion by 2030, driven by genetic testing, personalized medicine and faster clinical decision-making.

AGP

The artificial intelligence pathology quality control market is projected to grow from $1.78 billion in 2025 to $4.65 billion by 2030, according to The Business Research Company.

AGP

The Business Research Company says demand for Euvichol and Euvichol-Plus is being lifted by rising liver disease rates, broader screening and higher healthcare spending.

AGP

The Business Research Company says the global Epkinly market is set to grow through 2026-2035, led by rising demand for targeted oncology treatments and broader use of bispecific antibodies.

AGP

The Business Research Company says the artificial neural network market will grow from $0.68 billion in 2026 to $1.27 billion by 2030, driven by cloud adoption, real-time AI use cases and broader enterprise deployment.

AGP

The Business Research Company says the epoetin alfa market is being lifted by chronic disease prevalence, more drug approvals and expanding biosimilar use. North America led the market in 2025, while Asia-Pacific is expected to grow fastest…

AGP

The Business Research Company says the Evarrest market is set for growth through 2035 as surgery volumes rise, hospitals expand, and surgeons look for faster bleeding control.

AGP

The Business Research Company says the global Enspryng market is set to expand through 2035, driven by rising autoimmune and neurological diagnoses, broader biologics use, and stronger healthcare spending.

AGP

The Business Research Company says the global Erbitux market is on track to grow from $1.56 million in 2025 to $3.63 million by 2030, driven by rising cancer incidence and broader use of targeted oncology therapies.

AGP

The Business Research Company says the artificial intelligence clinical trial protocol feasibility tool market will grow from $0.83 billion in 2025 to $2.76 billion by 2030, driven by demand for faster trial approvals, lower costs and better…